Point-of-Care Testing

News on technologies and applications for point-of-care testing.

In a first clinical tryout, University of Turku researchers have shown that their assay has sensitivity and specificity levels on par with those of laboratory ELISAs.

The Phase II contract is for the further development of a portable multiplexed immunoassay system that would deliver a panel of host response biomarker results.

The immunoassay allows for the rapid detection of influenza types A and B antigens directly in nasal swab and nasopharyngeal swab specimens from symptomatic patients.

Neurovascular Diagnostics intends to commercialize a test for unruptured intracranial aneurysm tests that use RNA expression signatures.

Danish IVD firm BioPorto will distribute a version of its NGAL Test for use on the Cobas c 501/

Feb
27

In this webinar, Jill Viles, an Iowa mother with no clinical training, shares her story of how she self-diagnosed her rare condition, a muscle-wasting disease caused by a mutation in the LMNA gene. She will also discuss how she discovered that a mutation in the same gene is the underlying cause for the excess muscle phenotype exhibited by Canadian Olympic hurdler Priscilla Lopes-Schliep.